379 related articles for article (PubMed ID: 36034555)
1. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.
Grundy M; Narendran A
Front Pediatr; 2022; 10():910268. PubMed ID: 36034555
[TBL] [Abstract][Full Text] [Related]
2. Targeting hepatocyte growth factor/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies.
Yu J; Chen GG; Lai PBS
Med Res Rev; 2021 Jan; 41(1):507-524. PubMed ID: 33026703
[TBL] [Abstract][Full Text] [Related]
3. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
4. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
5. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
6. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
8. Targeting MET in cancer: rationale and progress.
Gherardi E; Birchmeier W; Birchmeier C; Vande Woude G
Nat Rev Cancer; 2012 Jan; 12(2):89-103. PubMed ID: 22270953
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
Zhang Y; Jain RK; Zhu M
Biomedicines; 2015 Mar; 3(1):149-181. PubMed ID: 28536405
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
Owusu BY; Galemmo R; Janetka J; Klampfer L
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28420162
[TBL] [Abstract][Full Text] [Related]
11. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
12. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer.
Elliott BE; Hung WL; Boag AH; Tuck AB
Can J Physiol Pharmacol; 2002 Feb; 80(2):91-102. PubMed ID: 11934261
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells.
Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z
Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869
[TBL] [Abstract][Full Text] [Related]
15. c-Met expression in renal cell carcinoma with bone metastases.
Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
[TBL] [Abstract][Full Text] [Related]
16. The role of HGF/c-MET signaling pathway in lymphoma.
Lam BQ; Dai L; Qin Z
J Hematol Oncol; 2016 Dec; 9(1):135. PubMed ID: 27923392
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
18. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.
Wang H; Rao B; Lou J; Li J; Liu Z; Li A; Cui G; Ren Z; Yu Z
Front Cell Dev Biol; 2020; 8():55. PubMed ID: 32117981
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.
Kim HJ
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630066
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
